300485 赛升药业
2024/06 - 中期
人民幣(K¥)
与去年同期
比较
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入214,837-21.03%476,570734,5471,050,8051,094,225
减:营业总成本205,073-21.08%517,648710,538945,017948,822
    其中:营业成本74,002-3.17%140,939171,608182,124177,340
               财务费用(491)43.92%(1,049)(451)(11,303)(13,311)
               资产减值损失----00--(938)
公允价值变动收益(90,107)-153.93%100,267125,409185,65214,812
投资收益(50,451)-150.88%59,80786,709132,78326,183
    其中:对联营企业和合营企业的投资收益(65,848)-172.24%46,91554,14691,724(1,511)
营业利润(129,160)-146.54%121,736254,636438,999179,916
利润总额(129,557)-146.68%122,163254,616439,024179,290
减:所得税费用(21,294)-176.06%25,75551,96643,89028,007
净利润(108,262)-143.38%96,408202,650395,134151,283
减:非控股权益(3,112)46.93%(6,510)(2,085)(7,136)(3,620)
股东净利润(105,150)-141.78%102,918204,735402,270154,903

市场价值指针
每股收益 (元) *-0.220-142.31%0.2100.4300.8400.320
每股派息 (元) *----0.0220.0860.1680.065
每股净资产 (元) *6.894-7.39%7.1347.0056.7365.822
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容